|
|
Post by peppy on Feb 26, 2019 16:01:47 GMT -5
peppy cannabidiol technosphere - various indications What do u think? peppy Cannabidiol Technosphere - various indications Single molecule CBD vs whole plant CBD-rich extract Single molecule CBD produces a bell-shaped, dose-response curve whereas whole plant CBD-rich extract does not. The entourage effect. Curious to see how RLS & MannKind's CBD Technosphere formulation performs and what indications they are targeting. I say, we take care of the children. www.screencast.com/t/q4SSH85oHd5but you knew that. |
|
|
|
Post by mango on Feb 26, 2019 16:14:59 GMT -5
peppy cannabidiol technosphere - various indications What do u think? peppy Cannabidiol Technosphere - various indications Single molecule CBD vs whole plant CBD-rich extract Single molecule CBD produces a bell-shaped, dose-response curve whereas whole plant CBD-rich extract does not. The entourage effect. Curious to see how RLS & MannKind's CBD Technosphere formulation performs and what indications they are targeting. I say, we take care of the children. www.screencast.com/t/q4SSH85oHd5but you knew that. Which types of epilepsy? Is that what Orrin Devinsky is for? Lennox-Gastaut syndrome? Dravet? |
|
|
|
Post by cretin11 on Feb 26, 2019 16:21:39 GMT -5
I would think we'd want the entourage effect for max benefit. On the other hand, that might make it more difficult to quantify precise dosage, etc.
|
|
|
|
Post by mango on Feb 26, 2019 23:42:14 GMT -5
I would think we'd want the entourage effect for max benefit. On the other hand, that might make it more difficult to quantify precise dosage, etc. You can with centrifugal partition chromatography, but I dunno of any company specifically doing that. I'm curious about what happened with the so-called proprietary compounds of Receptor's. Both Dronabinol and Cannabidiol are not proprietary compounds of Receptor. Did they end up not working, were they never developed or was it something else? We were told Receptor had proprietary compounds and they would be evaluated them using the Technosphere platform. MannKind has patents covering Technosphere with THC and CBD—so is MannKind still prevented from licensing Technosphere to someone else to use it with THC or CBD? I find it really hard to believe that dronabinol and cannabidiol are the compounds they were referring to 3 years ago. If so, shareholders were lied to, or if that is incorrect to say, then we were greatly misled. I don't mind operating in stealth and keeping things to a minimum if there's good reason for it, but I can't see how that applies here. • Is Technosphere technology being transferred to RLS? MannKind retains all rights for Technosphere technology, except for the use of our technology for the specific proprietary compounds of Receptor that are the subject of their license. www.mannkindcorp.com/Collateral/Documents/English-US/MNKD%202%203%2016%20Investor%20Call%20FAQ%20v2%209%2016%20FINAL.pdf• How will Technosphere technology be used by the licensee? Technosphere technology is to be used as a vehicle to deliver regulated doses of a proprietary compound to treat a variety of medical conditions, including chronic pain, spasticity and inflammatory diseases such as rheumatoid arthritis. • Is the agreement exclusive in any way? The agreement is exclusive only to the compounds used by the licensee, which are proprietary to them in any case. It does not prevent us from entering into other licensing agreements with other companies, even in the same therapeutic area, so long as they use different active compounds. www.mannkindcorp.com/Collateral/Documents/English-US/TS%20licensing%20FAQ.pdf• Matt P said on Feb 3, 2016, "They’re working closely with us to develop these proprietary compounds of theirs, and we feel pretty excited about it for reasons which ultimately become known, but there’s not much more beyond – I think we’ve kind of pushed the limits of what we’re allowed to say at this point, but I hope that will change in the near term." seekingalpha.com/article/3862956-mannkinds-mnkd-investor-conference-call-transcript |
|
|
|
Post by mango on Mar 13, 2019 22:47:10 GMT -5
I'm 100% certain that the Undisclosed Technosphere Formulation is not a PDE5 inhibitor. The umbrella of language under the TreT Agreement and the Research/Collab Agreement indicates that the Undisclosed Compound is not associated with and is out of the scope of the Agreement, which mean it does not pertain specifically to PAH. United is the one that is at liberty to have MannKind bring forward any of their drugs associated with PAH (it's in the Agreement), this Undisclosed Formulation is driven by MannKind (hence, it is OUTSIDE the scope of the original Agreement), and outside the scope of PAH in general for that matter. I encourage anyone doubting this to re-read United's and MannKind's latest 10Ks and all other relevant information.
I am now looking at the humanized (non-chimeric) version of dinutuximab for Neuroblastoma, Glioblastoma, Soft tissue sarcoma, and Melanoma. United has no patents covering Unituxin. I might post everything in Off Topic since it is way too much to post here.
Shout out to the person that dropped the dermatology drug...
|
|
|
|
Post by kpm1028 on Mar 13, 2019 23:12:23 GMT -5
 I am right in assuming 9,10,11 and 17 are 4 mnkd products? Can anyone make out the name for 17? |
|
|
|
Post by joeypotsandpans on Mar 13, 2019 23:22:24 GMT -5
I am right in assuming 9,10,11 and 17 are 4 mnkd products? Can anyone make out the name for 17? I believe it is Winilin |
|
|
|
Post by gamblerjag on Mar 13, 2019 23:23:16 GMT -5
I am right in assuming 9,10,11 and 17 are 4 mnkd products? Can anyone make out the name for 17? I believe it is Winilin . I love it “winning”. 😜 |
|
|
|
Post by mango on Mar 14, 2019 0:20:16 GMT -5
I am right in assuming 9,10,11 and 17 are 4 mnkd products? Can anyone make out the name for 17? 11 isn't MannKind's, but I would add 14 (along with 15 as a potential maybe) to the list |
|
|
|
Post by mytakeonit on Mar 14, 2019 0:42:25 GMT -5
Looks like WTAVLIV
|
|
|
|
Post by hellodolly on Mar 14, 2019 8:53:05 GMT -5
I'm 100% certain that the Undisclosed Technosphere Formulation is not a PDE5 inhibitor. The umbrella of language under the TreT Agreement and the Research/Collab Agreement indicates that the Undisclosed Compound is not associated with and is out of the scope of the Agreement, which mean it does not pertain specifically to PAH. United is the one that is at liberty to have MannKind bring forward any of their drugs associated with PAH (it's in the Agreement), this Undisclosed Formulation is driven by MannKind (hence, it is OUTSIDE the scope of the original Agreement), and outside the scope of PAH in general for that matter. I encourage anyone doubting this to re-read United's and MannKind's latest 10Ks and all other relevant information. I am now looking at the humanized (non-chimeric) version of dinutuximab for Neuroblastoma, Glioblastoma, Soft tissue sarcoma, and Melanoma. United has no patents covering Unituxin. I might post everything in Off Topic since it is way too much to post here. Shout out to the person that dropped the dermatology drug... Mango..I mentioned Dupixent for the treatment of Atopical Dermititis (Eczema) but I don't think it was under this topic. Where you referring to that treatment? If it wasn't my bad...if it was, it was based on the delivery of injections and how TS can be a game changer in that space. |
|
|
|
Post by kpm1028 on Mar 14, 2019 14:53:43 GMT -5
 Wonder when the down payment on this might come in |
|
|
|
Post by mytakeonit on Mar 14, 2019 15:16:34 GMT -5
I stand corrected ... how did you blow it up so clear? Now can you blow up my bank account so I can buy more shares?
|
|
|
|
Post by mango on Mar 14, 2019 17:43:07 GMT -5
I'm 100% certain that the Undisclosed Technosphere Formulation is not a PDE5 inhibitor. The umbrella of language under the TreT Agreement and the Research/Collab Agreement indicates that the Undisclosed Compound is not associated with and is out of the scope of the Agreement, which mean it does not pertain specifically to PAH. United is the one that is at liberty to have MannKind bring forward any of their drugs associated with PAH (it's in the Agreement), this Undisclosed Formulation is driven by MannKind (hence, it is OUTSIDE the scope of the original Agreement), and outside the scope of PAH in general for that matter. I encourage anyone doubting this to re-read United's and MannKind's latest 10Ks and all other relevant information. I am now looking at the humanized (non-chimeric) version of dinutuximab for Neuroblastoma, Glioblastoma, Soft tissue sarcoma, and Melanoma. United has no patents covering Unituxin. I might post everything in Off Topic since it is way too much to post here. Shout out to the person that dropped the dermatology drug... Mango..I mentioned Dupixent for the treatment of Atopical Dermititis (Eczema) but I don't think it was under this topic. Where you referring to that treatment? If it wasn't my bad...if it was, it was based on the delivery of injections and how TS can be a game changer in that space. Not that drug, but it made me look at the Unutuxin cancer indications more closely, which led me to the 13-cis-retinoic acid (Accutane). It's used in the neuroblastoma regimen that United talks about, it's also well known for treating acne. |
|
